Literature DB >> 8363355

Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.

C I Wright1, C Geula, M M Mesulam.   

Abstract

Butyrylcholinesterase (BChE) and an altered form of acetylcholinesterase (AChE) accumulate in the plaques and tangles of Alzheimer's disease (AD). The sources for these plaque- and tangle-bound cholinesterases have not been identified. We now report that AChE and BChE activities with pH preferences and inhibitor selectivities identical to those of plaque- and tangle-bound cholinesterases are found in the astrocytes and oligodendrocytes of control and AD brains. These glial-type cholinesterases are selectively inhibited by indolamines and protease inhibitors. In control brains glial-type cholinesterases appear confined to the intracellular space, whereas in patients with AD they decorate plaques and tangles as well. In control and AD brains AChE-positive glia are distributed throughout the cortical layers and subcortical white matter, whereas BChE-positive glia reach high densities only in the deep cortical layers and white matter. In non-AD control brains, the ratio of BChE to AChE glia was higher in entorhinal and inferotemporal cortex, two regions with a high susceptibility to the pathology of AD, than in primary somatosensory and visual cortex, two areas with a relatively lower susceptibility to the disease process. There was no age-related differences in the density or distribution of cholinesterase-positive glia. In comparison with age-matched control specimens, AD brains had a significantly higher density of BChE glia and a lower density of AChE glia in entorhinal and inferotemporal regions but not in the primary somatosensory or visual areas. These results suggest that glia constitute a likely source for the cholinesterase activity of plaques and tangles and that a high ratio of BChE- to AChE-positive glia may play a permissive or causative role in the neuropathology of AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363355     DOI: 10.1002/ana.410340312

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  43 in total

1.  Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.

Authors:  Katsuyoshi Mizukami; Hiroyasu Akatsu; Eric E Abrahamson; Zhiping Mi; Milos D Ikonomovic
Journal:  Neuropathology       Date:  2015-08-21       Impact factor: 1.906

Review 2.  Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors?

Authors:  M Zimmermann
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.

Authors:  Bin He; Sylvia E Perez; Sang H Lee; Stephen D Ginsberg; Michael Malek-Ahmadi; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2020-05-05       Impact factor: 3.215

4.  Characterization of a complete cycle of acetylcholinesterase catalysis by ab initio QM/MM modeling.

Authors:  Alexander V Nemukhin; Sofia V Lushchekina; Anastasia V Bochenkova; Anna A Golubeva; Sergei D Varfolomeev
Journal:  J Mol Model       Date:  2008-03-15       Impact factor: 1.810

Review 5.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

6.  Effect of long-term exposure to aluminum on the acetylcholinesterase activity in the central nervous system and erythrocytes.

Authors:  R R Kaizer; M C Corrêa; L R S Gris; C S da Rosa; D Bohrer; V M Morsch; Maria Rosa Chitolina Schetinger
Journal:  Neurochem Res       Date:  2008-05-10       Impact factor: 3.996

Review 7.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 8.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.

Authors:  Krista L Lanctôt; Nathan Herrmann; Kenneth K Yau; Lyla R Khan; Barbara A Liu; Maysoon M LouLou; Thomas R Einarson
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

9.  Amyloid-beta expression in retrosplenial cortex of triple transgenic mice: relationship to cholinergic axonal afferents from medial septum.

Authors:  R T Robertson; J Baratta; J Yu; F M LaFerla
Journal:  Neuroscience       Date:  2009-09-20       Impact factor: 3.590

10.  The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

Authors:  Erez Podoly; Deborah E Shalev; Shani Shenhar-Tsarfaty; Estelle R Bennett; Einor Ben Assayag; Harvey Wilgus; Oded Livnah; Hermona Soreq
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.